文献速递前列腺癌

中危前列腺癌PSA 10-20 ng/mL主动监测的病理结局分析

Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL: pathological outcome analysis of a population-level database.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-09-10

基于SEER-AS数据库26,548例接受主动监测后行根治性前列腺切除术的局限性前列腺癌患者,比较PSA 10-20 ng/mL且GG1与PSA<10 ng/mL且GG2患者的不良病理风险。多因素分析显示,PSA 10-20 ng/mL(OR 1.87,95%CI 1.71-2.05,p<0.001)的不良病理风险低于GG2(OR 2.56,95%CI 2.40-2.73,p<0.001)。结果支持将主动监测标准更宽松地扩展至经严格选择的PSA 10-20 ng/mL且GG1患者。

要点

  • PSA 10-20 ng/mL且GG1患者不良病理风险低于PSA<10 ng/mL且GG2患者。
  • 多因素分析中PSA 10-20 ng/mL的OR为1.87,低于GG2的OR 2.56。
  • 可考虑将主动监测标准更宽松地扩展至经严格选择的PSA 10-20 ng/mL且GG1患者。

核心结论

  • 结果支持将主动监测标准更宽松地扩展至经严格选择的PSA 10-20 ng/mL且GG1患者。

研究设计与样本

  • 从SEER前列腺癌主动监测数据库纳入26,548例初治为主动监测、年龄<80岁、临床局限(cT1-2cN0M0)、PSA≤20 ng/mL、活检GG≤2且阳性穿刺针比例≤33%、后转为根治性前列腺切除术的男性。

主要发现

  • GG1且PSA 10-20 ng/mL的1731例中382例(22.1%)存在不良病理。
  • GG2且PSA<10 ng/mL的8367例中2340例(28%)存在不良病理。
  • 多因素分析中PSA 10-20 ng/mL的OR为1.87(95%CI 1.71-2.05,p<0.001),低于GG2的OR 2.56(95%CI 2.40-2.73,p<0.001)。

临床怎么用

  • 对经严格选择的PSA 10-20 ng/mL且GG1患者,可考虑更宽松地纳入主动监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Active surveillance (AS) is generally recognized as the preferred option for men with low-risk prostate cancer. Current guidelines use prostate-specific antigen (PSA) of 10-20 ng/mL or low-volume biopsy Gleason grade group (GG) 2 as features that, in part, define the favorable intermediate-risk disease and suggest that AS may be considered for some men in this risk category. METHODS: We identified 26,548 men initially managed with AS aged <80 years, with clinically localized prostate cancer (cT1-2cN0M0), PSA ≤ 20 ng/mL, biopsy GG ≤ 2 with percent positive cores ≤33% and who converted to treatment with radical prostatectomy from the surveillance, epidemiology, and end results prostate with the watchful waiting database. Multivariable logistic regression was performed to determine predictors of adverse pathology at RP according to PSA level (<10 vs 10-20 ng/mL) and GG (1 vs 2). RESULTS: Of 1731 men with GG 1 disease and PSA 10-20 ng/mL, 382 (22.1%) harbored adverse pathology compared to 2340 (28%) of 8,367 men with GG 2 and a PSA < 10 ng/mL who had adverse pathology at RP. On multivariable analysis, the odds of harboring adverse pathology with a PSA 10-20 ng/mL (odds ratio [OR] 1.87, 95% confidence interval [CI] 1.71-2.05, p < 0.001) was less than that of GG 2 (OR 2.56, 95%CI 2.40-2.73, p < 0.001) after adjustment. CONCLUSIONS: Our results support extending AS criteria more permissively to carefully selected men with PSA 10-20 ng/mL and GG 1 disease.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Lonergan PE, Jeong CW, Washington SL, et al. Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL: pathological outcome analysis of a population-level database. Prostate Cancer Prostatic Dis. 2021. PMID: 34508180. doi:10.1038/s41391-021-00448-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。